Candel Therapeutics Announces Publication in The Lancet Oncology of Pivotal Phase 3 Data Demonstrating Significant Improvement in Disease-Free Survival with Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer
StockNews.AI · 2 hours
AI Summary
The Lancet Oncology publication confirms phase 3 results that aglatimagene plus radiotherapy improves disease-free survival in localized prostate cancer. With 745 patients and a planned BLA filing in Q4 2026, the data strengthen regulatory and commercialization prospects and could meaningfully boost CADL's valuation on a transformative immunotherapy approach.
Sentiment Rationale
Strong, peer-reviewed phase 3 data (30% DFS, 38% prostate cancer-specific DFS) paired with a clear regulatory path (BLA 4Q26) and large trial size (N=745) increases probability of FDA approval and commercial upside, likely attracting buying interest and re-rating CADL’s multiple.
Trading Thesis
Long CADL on strong trial data and upcoming 4Q2026 BLA filing; near-term catalysts.
Market-Moving
- Peer-reviewed validation from a top oncology journal supports regulatory momentum.
- Regulatory path into the U.S. with a planned BLA submission in 4Q26.
- Large Phase 3 dataset (N=745) substantiates clinical benefit and safety.
Key Facts
- Lancet Oncology reports 30% DFS improvement with aglatimagene plus radiotherapy.
- Prostate cancer-specific DFS up 38% (HR 0.62, p=0.0046).
- Biopsy-based complete response: 80% vs 63% in control after ~2 years.
- BLA submission for aglatimagene planned for Q4 2026; safety favorable.
Companies Mentioned
- Candel Therapeutics, Inc. (CADL): Lead candidate aglatimagene CAN-2409 shows phase 3 efficacy signals; BLA planned 4Q26.
- Lancet Oncology (N/A): Peer-reviewed publication validates data; supports regulatory and investor confidence, not a direct stock driver.
Industry News
Category: Industry News. Fits as a major clinical-data and regulatory milestone for a clinical-stage biotech, with potential near-term stock impact given the BLA timing and peer-reviewed validation.